Establishment and utility of SwedAD: a nationwide Swedish registry for patients with atopic dermatitis receiving systemic pharmacotherapyDermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Sweden.
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Dermatology and Venerology.
Carlanderska Hospital, Gothenburg, Sweden.
Department of Dermatology and Venereology, County Council of Östergötland, Linköping, Sweden.
Department of Dermatology and Venereology, Skåne University Hospital, Lund, Sweden.
Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.
Department of Medical Sciences, Section of Dermatology, Uppsala University, Uppsala, Sweden.
Patients' organization Atopikerna, Swedish Asthma and Allergy Association, Stockholm, Sweden.
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2023 (English)In: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 103, article id adv7312
Article in journal (Refereed) Published
Abstract [en]
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.
Place, publisher, year, edition, pages
Medical Journals Sweden AB , 2023. Vol. 103, article id adv7312
Keywords [en]
dupilumab, Janus kinase inhibitors, methotrexate, real-world data, registries
National Category
Dermatology and Venereal Diseases
Research subject
Dermatology and Venerology
Identifiers
URN: urn:nbn:se:umu:diva-206800DOI: 10.2340/actadv.v103.7312ISI: 000972092100013PubMedID: 37021597Scopus ID: 2-s2.0-85151799627OAI: oai:DiVA.org:umu-206800DiVA, id: diva2:1751199
Funder
Swedish Asthma and Allergy AssociationKarolinska Institute2023-04-172023-04-172023-09-05Bibliographically approved